The study, published July 14 in Critical Care Explorations, found that Cytovale’s IntelliSep Index sepsis test was also cheaper than alternative solutions, at just $3,849 per patient as opposed to the widely-available, alternative procalcitonin sepsis test’s 94 percent survival rate and cost of $4,656 per patient.
“For patients who have sepsis, getting sent home from the hospital is very serious because they can suffer multiple-organ failure within hours,” Christopher Hollenbeak, PhD, study lead and a professor of health policy and administration at the Penn State College of Health and Human Development stated in a Sept. 25 news release. “Every year, there are patients who enter the emergency department of a hospital, present with a limited number of sepsis symptoms and are sent home. This test could save many of those people’s lives.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.